Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Ronald D. Hart"'
Autor:
Linda Sutton, Lynn G. Dressler, Patricia A. Kartcheske, Julie R. Gralow, Aminah Jatoi, Ronald D. Hart, Heshan Liu, Maria Theodoulou, Alice B. Kornblith, C. Cirrincione, Barbara A. Parker, Ann M. Mauer, Edith A. Perez, Ahmad A. Mahmood, Arti Hurria, Mei Yin C. Polley, Debjani Grenier, Donald A. Berry, Lisa A. Carey, Larry Norton, Hyman B. Muss, Clifford A. Hudis, Gustav Magrinat, Harold J. Burstein, Harvey J. Cohen, Eric P. Winer, Ann H. Partridge, Antonio C. Wolff
PURPOSE Older women with breast cancer remain under-represented in clinical trials. The Cancer and Leukemia Group B 49907 trial focused on women age 65 years and older. We previously reported the primary analysis after a median follow-up of 2.4 years
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e78d83708f8da175563c5bd878d26f78
https://europepmc.org/articles/PMC6900836/
https://europepmc.org/articles/PMC6900836/
Autor:
Ari David Baron, Aparna Keshaviah, Rebecca Gelman, Harold J. Burstein, Rosemary Lambert-Falls, Ronald D. Hart, Eric P. Winer, P. Kelly Marcom
Publikováno v:
Cancer. 110:965-972
BACKGROUND. The optimal trastuzumab-based chemotherapy regimen for HER2-overexpressing, metastatic breast cancer is not known. The trastuzumab and vinorelbine or taxane (TRAVIOTA) study was a prospective, multicenter, randomized trial that was design
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67dcd01cac0a1f2c55ed50abf3fdbb21
https://doi.org/10.1002/cncr.22885
https://doi.org/10.1002/cncr.22885
Autor:
William C. Wood, Daniel R. Budman, Ann H. Korzun, M. Robert Cooper, Jerry Younger, Ronald D. Hart, Anne Moore, John A. Ellerton, Larry Norton, Carolyn R. Ferree, Anita Colangelo Ballow, Emil Frei, I. Craig Henderson
Publikováno v:
New England Journal of Medicine. 330:1253-1259
Adjuvant chemotherapy is widely used for breast cancer and is known to extend survival. Some clinicians seek a greater survival benefit by increasing the intensity of the dose, whereas others lower it to diminish toxicity.The Cancer and Leukemia Grou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01b2b81d8197d47833404af725435e5d
https://doi.org/10.1056/nejm199405053301801
https://doi.org/10.1056/nejm199405053301801
Autor:
Hyman B, Muss, Donald A, Berry, Constance T, Cirrincione, Maria, Theodoulou, Ann M, Mauer, Alice B, Kornblith, Ann H, Partridge, Lynn G, Dressler, Harvey J, Cohen, Heather P, Becker, Patricia A, Kartcheske, Judith D, Wheeler, Edith A, Perez, Antonio C, Wolff, Julie R, Gralow, Harold J, Burstein, Ahmad A, Mahmood, Gustav, Magrinat, Gutav, Magrinat, Barbara A, Parker, Ronald D, Hart, Debjani, Grenier, Larry, Norton, Clifford A, Hudis, Eric P, Winer, R K, Shadduck
Older women with breast cancer are underrepresented in clinical trials, and data on the effects of adjuvant chemotherapy in such patients are scant. We tested for the noninferiority of capecitabine as compared with standard chemotherapy in women with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34631a7e4949d319b10b924c9532c7d4
Autor:
Mark J. Ratain, Rosemarie Mick, Richard J. Jones, Jan Marie McEvilly, Howard Ozer, Leonidas C. Platanias, Ronald D. Hart, Carole B. Miller
Publikováno v:
Journal of Clinical Oncology. 9:2021-2026
Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b5f9ad49326445a77982172a74b678b
https://doi.org/10.1200/jco.1991.9.11.2021
https://doi.org/10.1200/jco.1991.9.11.2021
Autor:
Harold J. Burstein, Eric P. Winer, Rosemary Lambert-Falls, Paul K. Marcom, Ronald D. Hart, Ari David Baron, Rebecca Gelman, Aparna Keshaviah
Publikováno v:
Journal of Clinical Oncology. 24:650-650
650 Background: The optimal trastuzumab/chemotherapy regimen for advanced breast cancer is not known. We performed a multicenter, randomized clinical trial to compare TRastuzumab And VInorebline Or TAxane (TRAVIOTA) chemo- and bio-therapy combination
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eaf9f1a43c3c5aea06e9ccffb7440230
https://doi.org/10.1200/jco.2006.24.18_suppl.650
https://doi.org/10.1200/jco.2006.24.18_suppl.650
Publikováno v:
Cancer. 48:1522-1527
Twenty-nine postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy underwent treatment with a combination of vinblastine, Adriamycin, thiotepa, and Halotestin given once every 21 days. Thirteen patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::178f154cad8e81ea0c5e149cce129086
https://doi.org/10.1002/1097-0142(19811001)48:7<1522::aid-cncr2820480709>3.0.co
https://doi.org/10.1002/1097-0142(19811001)48:7<1522::aid-cncr2820480709>3.0.co
Publikováno v:
Cancer. 42:2534-2537
Nineteen postmenopausal patients with metastatic breast cancer refractory to conventional combination chemotherapy were treated with monthly cycles with the combinations of vinblastine, adriamycin, thiotepa and halotestin. Ten patients (52%) responde
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7d14dfb79bf6237cb4b94d50262d828d
https://doi.org/10.1002/1097-0142(197812)42:6<2534::aid-cncr2820420605>3.0.co
https://doi.org/10.1002/1097-0142(197812)42:6<2534::aid-cncr2820420605>3.0.co
Publikováno v:
Journal of analytical toxicology. 4(3)
Methylglyoxal-bis(guanylhydrazone), Methyl-G, is a potent antineoplastic agent currently undergoing Phase l clinical trials. Serum, ascitic and pleural fluids, and urine are deproteinized with methanol, supernatant is evaporated, residue is redissolv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd635d804318902f7e57a9392a6536f9
https://pubmed.ncbi.nlm.nih.gov/6999237
https://pubmed.ncbi.nlm.nih.gov/6999237